Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MGC028 · 1 trial · 5 indications
Types of AEs include Serious Adverse Events (SAEs), and AEs Leading to Treatment Delay or Discontinuation or Dose Reduction, dose limiting toxicities, and AEs of Special Interest. Observation of side effects determines the highest safe dose for further study
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Dose level 1 of MGC028, IV |
| Cohort 2 | EXPERIMENTAL | Dose level 2 of MGC028, IV |
| Cohort 3 | EXPERIMENTAL | Dose level 3 of MGC028, IV |
| Cohort 4 | EXPERIMENTAL | Dose level 4 of MGC028, IV |
| Cohort 5 | EXPERIMENTAL | Dose level 5 of MGC028, IV |
| Cohort 6 | EXPERIMENTAL | Dose level 6 of MGC028, IV |
| Expansion Cohort 1 | EXPERIMENTAL | MTD or MAD of MGC028, IV |
| Expansion Cohort 2 | EXPERIMENTAL | MTD or MAD of MGC028, IV |
| Expansion Cohort 3 | EXPERIMENTAL | MTD or MAD of MGC028, IV |
| Name | Type | Description |
|---|---|---|
| MGC028 | BIOLOGICAL | MGC028 is an antibody-drug conjugate targeted against ADAM9. |
Inclusion Criteria: * Participants in dose escalation or supplemental cohorts must have histologically proven unresectable, locally advanced or metastatic solid tumor limited to one of the following types: NSCLC adenocarcinoma, cholangiocarcinoma, colorectal carcinoma (CRC), or pancreatic carcinoma...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
MGC028 is an investigational monoclonal antibody being studied for the treatment of advanced solid tumors, including NSCLC adenocarcinoma, cholangiocarcinoma, pancreatic carcinoma, and colorectal carcinoma. It is currently in Phase 1 clinical development and has not been approved by the FDA.
MGC028 targets ADAM9, a protein involved in tumor progression. As a monoclonal antibody, it is designed to bind to this target. The drug is being evaluated in a Phase 1 clinical trial for its safety and efficacy in patients with advanced solid tumors.
MGC028 is being developed by MacroGenics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol MGNX. The company is currently conducting a Phase 1 clinical trial to evaluate the drug in patients with advanced solid tumors.
MGC028 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 trial is recruiting participants with advanced solid tumors to assess the drug's safety, tolerability, and preliminary efficacy.
MGC028 is being studied in a Phase 1 clinical trial with the identifier NCT06723236, titled 'A Study of MGC028 in Participants With Advanced Solid Tumors.' The trial is recruiting 124 participants in the United States and is open to adults aged 18 years and older.
MGC028 is a monoclonal antibody that targets ADAM9. It is not known by any other names. The drug is being developed specifically for advanced solid tumors and is currently in Phase 1 clinical trials.